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Abstract
  
 Breast cancer with Human Epidermal Growth Factor Receptor (HER)2 overexpression 
increases tumor progession and lead to metastasis, which is primarily cause of mortality 
in breast cancer. Pentagamaboronon-0 Sorbitol (PGB-0-So) is an aquoeous formulation of 
curcumin analog, PGB-0, with sorbitol. This compound has been developed as an anti-
cancer chemotherapeutic agent and a boron carrying pharmaceutical for boron neutron 
capture therapy (BNCT). The aim of this study is to investigate anti-metastatic activities 
of PGB-0-So against HER2-overexpressed MCF-7 breast cancer (MCF-7/HER2) cells. The 
MTT cytotoxicity assay of PGB-0-So exhibited cytotoxic effect with an IC50 value of 35 μM. 
The testing of anti-migration activity using the scratch wound healing assay demonstrated 
that PGB-0-So inhibited the closure of the wound on MCF-7/HER2 cells compare to the 
control. Furthermore, PGB-0-So was able to suppress matrix metalloproteinase (MMP)-9 
activities, based on the gelatin zymography assay. In conclusion, PGB-0-So has potency 
to be developed as an anti-cancer agent against metastatic breast cancer. 
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INTRODUCTION
 Human Epidermal Growth Factor Receptor 2 
(HER2) overexpression is found in approximately 
20-30% of cases of breast cancer. HER2-positive 
breast cancer shows worse prognosis leading to 
aggressive disease that causes chemo-resistant 
(Yokoyama, et al., 2006) and increased metastasis 
(Wolf-Yadlin, et al., 2006). Moreover, failure of 
metastasis prevention primarily caused mortality in 
breast cancer. 
 The treatment of metastasis in breast cancer was 
conducted by chemotherapy, such as doxorubicin 
which performed strong cytotoxicity against 
cancer cells.  Despite its potent anticancer activity, 
doxorubicin had several limitations for long-term 
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use including cardiotoxicity and chemoresistance 
(Carvalho, et al., 2009; Thorn, et al., 2011). In 
addition, low dose of doxorubicin induces epithelial-
mesenchymal transition (EMT) and lamellipodia 
formation leading to metastasis on breast cancer 
cells (MBC) (Bandyopadhyay, et al., 2010, Amalina, 
et al., 2017). Hence, several anti-metastatic agents 
had been developed to treat MBC.
  Development of anti-metastatic agents as 
potential candidate of chemotherapeutic agents has 
been established over the years. Patients characterized 
as metastatic HER2-positive breast cancer are 
treated specifically with anti-HER2 either alone or in 
combination with chemotherapy, especially taxanes. 
Unfortunately, specific anti-HER2 therapy, such as 
Trastuzumab, also caused resistance through various 
mechanisms (Luque-Cabal, et al., 2016). Similar to 
doxorubicin, taxanes in low dose induced peripheral 
neuropathy in breast cancer (Bhatnagar, et al., 2014), 
while platinum compound, such as cisplatin, induced 
EMT in ovarian cancer (Baribeau, et al., 2014). 
Thus, the effective anti-metastatic agents need to be 
developed further.
  Curcumin analog based on benzylidine 
cyclopentanone backbone such as Pentagamavunon-0 
(PGV-0) and Pentagamavunon-1 (PGV-1) exert 
potent cytotoxic and anti-metastatic activities toward 
several types of breast cancer cells (Meiyanto, et al., 
2014; Putri, et al., 2016). Pentagamaboronon-0 (PGB-
0) is a novel curcumin analog based on benzylidine 
cyclopentanone and boron atom substitution 
developed by Cancer Chemoprevention Research 
Center, Faculty of Pharmacy, Universitas Gadjah 
Mada (Utomo, et al., 2017). This compound has 
been developed as an anti-cancer chemotherapeutic 
agent and boron carrying pharmaceutical for boron 
neutron capture therapy (BNCT). PGB-0 is reported 
to be able to interact with HER2 ATP-binding sites 
and decrease HER2 expression on the MCF-7/HER2 
cells (Utomo, et al., 2017). Cytotoxicity of PGB-
0 toward HER2-positive breast cancer had been 
determined. PGB-0 also performed anti-metastatic 
activity toward triple negative breast cancer cells. 
However, like curcumin, PGB-0 has less solubility 
in water. To improve the solubility of PGB-0, we 
synthesized the aquoeus formulation of  PGB-0 
with polyol sugar, sorbitol, namely PGB-0-So. As 
curcumin analogue, this compound is potential to 
be examined as an anti-cancer agent. In this study 
we aim to investigate the anti-metastatic activities 
of PGB-0-So against HER-2-overexpressed breast 
cancer cells. 
MATERIALS AND METHODS
Cell Cultures
 MCF-7/HER2 breast cancer cell lines were 
obtained from Prof. Masashi Kawaichi, Nara 
Institute of Science and Technology (NAIST), 
Japan. Cells were maintained with Dulbecco’s 
Modified Eagle’s Media (Gibco,New York,USA) 
high glucose supplemented by 10% Bovine Fetal 
Serum (Sigma-Aldrich, St. Leuis, USA), penicillin-
streptomycin 1,5% v⁄v (Gibco, New York, USA), 
Fungizone 0,5% v⁄v (Gibco, New York, USA). Cells 
were incubated at 37oC with 5% CO2. Samples used 
were sorbitol (Sigma-Aldrich, St. Leuis, USA), 
chemically synthesized Pentagamaboronon-0-
Sorbitol (PGB-0-So) (the purity is ≥93%) was 
obtained from Cancer Chemoprevention Research 
Center (CCRC), Faculty of Pharmacy, Universitas 
Gadjah Mada and Doxorubicin (Sigma-Aldrich, St. 
Leuis, USA). 
Cytotoxicity Assay
 Cytotoxicity assay was conducted using 
MTT assay (Mosmann, 1983). Briefly, a 96-well 
microplate was seeded with 2x103 MCF-7/HER2 
cells suspended in 100 μL per well and incubated 
overnight. On the following day, the cells were 
treated with PGB-0-So at various concentration and 
incubated for 24 hours (h) at 37oC with 5% CO2. 
Then, 100 μL  of  0.5 mg/mL 3-(4,5-dimethylthiazzol-
2yl)-2,5-tidiphenyltetrazolium (MTT) reagent 
(Biovision, California, USA) were added and the 
cells were incubated for 2 h. The reaction was 
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stopped by adding SDS stopper solution containing 
0.01N HCl and incubated overnight. The absorbance 
then being measured using a plate reader (BioRad, 
California, USA)  at 595 nm.
Cell Migration Assay 
 The 8.5x104 MCF-7/HER2 cells were seeded 
into 24-well plate and incubated for 24 h. Cell 
starvation was performed by incubating cells on 
medium containing 0.5% FBS. Cells were scratched 
using a sterile yellow tip and treated with the 
different concentrations of PGB-0-So, are: ½ IC50 
(18 μM); ¼ IC50 (9 μM); 1/8 IC50 (4.5 μM), 10 nM 
doxorubicin or the combination of  both for 24 h. 
The closures of each scratched area were observed 
at 0, 18, 24 and 42 h after treatment under inverted 
microscope (Olympus, Tokyo, Japan) and captured 
by a digital camera (Samsung®, Seoul, South 
Korea). Then further analyzed using ImageJ 1.51j8 
java 1.8.0_112 and IBM SPSS Statistics program.  
MMP-9 Protein Activity Assay
 The assay of MMP-9 activity in the MCF-7/
HER2 culture media was performed using gelatin 
zymography. The culture media were obtained 
from the MCF-7/HER2 cells that were treated with 
estardiol (Sigma-Aldrich, St. Leuis, USA) in order 
to increase MMP-9 expression (Nilsson, et al., 
2007), different concentrations of PGB-0-So, are: 
½ IC50 (18 μM); ¼ IC50 (9 μM); 1/8 IC50 (4.5 μM), 
10 nM doxorubicin or the combination of  them 
for 24 h. Then, the culture media were subjected 
to 8% SDS-PAGE supplemented with 0.1% gelatin. 
Following the electrophoresis, gel was incubated 
with 2% of Triton-X 100 (Merck, New Jersey, USA) 
in water for 30 minutes at room temperature and the 
gel was then removed from solution. Furthermore, 
incubation buffer, consist of 40 mM Tris-HCl pH 8, 
10 mM CaCl2, 0.02% NaN3, was added to gel and 
incubated again at 37°C for 18-20 h. Then, the gel 
was stained using Coomassie Brilliant Blue R-250 
solution and de-stained until clear bands with blue 
background were observed. Those bands were 
documented and analyzed using ImageJ 1.51j8 java 
1.8.0_112software.
RESULTS
Cytotoxic Effect of PGB-0-So 
 Characterization The compounds used in the 
cytotoxic assay in this study were sorbitol and PGB-
0-So. Based on the correlation graph between the 
concentration of the compound and the precentage 
ofcell viability (Figure 1B), treatment with sorbitol 
did not show a decrease in the percent viability of 
MCF-7/HER2 cells, so it can be stated that sorbitol 
does not have cytotoxic effect on the cells. In 
contrast, PGB-0-So treatment  at the concentrations 
of 2.96 - 59.22 μM gave cytotoxic effects toward 
MCF-7/HER2 cells in a dose-dependent manner 
with IC50 value of 35 μM. The decreased viability 
of MCF-7/HER2 cells can also be seen from the 
changes of cell morphology after treatment with 
PGB-0-So for 24 h compared to the untreated group 
(Figure 1A).
Anti-migratory Effect of PGB-0-So
 According to the cell migration assay, a single 
treatment of PGB-0-So and its combination with 
Dox were able to inhibit the migration of MCF-7/
HER2 cells (Figure 2A). At  42 h observation, a 
single treatment with a concentration of  1/8 IC50 (4.5 
μM) and ½ IC50 (18 μM) PGB-0-So significantly 
inhibited cell migration compared to the control 
group with a percentage of closure of 58% and 71% 
(Figure 2B), respectively. At the same observation 
time (42 h), the combination treatment of 4.5 μM 
or 18 μM PGB-0-So with 10 nM Dox also showed 
significant inhibition of cell migration compared to 
the control group with the percentages of closure of 
47% and 46%, respectively (Figure 2B).
MMP-9 Activity
 MMP-9 activity analysis exhibited that a 
single PGB-0-So treatment and its combination 
with 10 nM Dox were able to inhibit MMP-9 
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Figure 1. Cytotoxic effect of Pentagamaboronon-0-Sorbitol (PGB-0-So) toward MCF-7/HER2 cells. A: The cell 
morphology after treatment with PGB-0-So in various concentrations. B: Cytotoxic profile of Sorbitol and PGB-
0-So on MCF-7/HER2 cells describing correlation between concentration and cell viability. PGB-0-So performed 
cytotoxic effect with IC50 value of 35 μM. 
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activities (Figure 3A). At 24 h of treatment, PGB-
0-So both single treatment and its combination with 
Dox inhibited MMP-9 activity in a dose-dependent 
manner when compared to the control group (Figure 
3B). Thus, high concentration PGB-0-So has anti-
metastatic ability by inhibiting MMP-9 activity.
DISCUSSION
 Cytotoxicity assay of PGB-0-So was 
conducted as early screening for this compound 
potency against MCF-7/HE2 cell lines. The results 
exhibited that the cytotoxic effect of PGB-0-So on 
MCF-7/HER2 cells was greater than that of PGB-0. 
PGB-0-So has an average value of IC50 35 μM while 
IC50 PGB-0 was still quite large, 270 μM (Utomo, 
et al., 2017). This may be due to the increased 
solubility of PGB-0-So, since the solubility of 
a compound has an effect on its absorption and 
bioactivity in the body (Shangguan, et al., 2017). 
The cytotoxic activity of PGB-0 is probably 
caused by the interaction of the compound with 
ATP binding site of HER2 protein MCF-7/HER2 
cells (Utomo, et al., 2017). With the increased 
cytotoxic effects of PGB-0-So on MCF-7/HER2 
cells compared to PGB-0 it is thought to be due to 
other pathways involved in its cytotoxic activity, 
via the caveolae-mediated pathway. Caveolae is 
a protein on the surface of cell membranes that is 
reportedly able to interact specifically with sorbitol 
and contribute to the occurrence of endocytosis 
(Nguyen, et al., 2014). Caveolae is found to be 
overexpressed in most cancer cells (Patlolla, et al., 
2004; Waalkes, et al., 2011) and one of them in 
breast cancer cells MCF-7 (Nguyen, et al., 2014). 
The presence of a specific interaction of sorbitol 
with the caveolae protein followed by endocytosis 
allows for increased cellular uptake of PGB-0-So 
into MCF-7/HER2 cancer cells, thus increasing 
the cytotoxic effect of the compound. However, 
for further research it is still necessary to test the 
mechanism of entry of PGB-0-So compounds into 
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Figure 2. The effect of PGB-0-So cell migration toward MCF-7/HER2 cells. Cell migration assay was conducted using 
wound healing assay as described in the methods. A: Inhibitory activity of cell migration after treatment with 
4.5 μM, 18 μM PGB-0-So, and its combination with 10 nM Doxorubicin. B: Quantification of closure precentage 
on each treatment at  42 h. Statistical analysis of % closure on each treatment at 42 h (*p<0.05) by ANOVA one 
way test compared to untreated cells. PGB-0-So exhibited inhibitory effect on cell migration at 4.5 μM and 18 
μM concentration either in single or combination with 10 nM Doxorubicin at 42 h. 
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Figure 3. The effect of PGB-0-So on the MMP-9 Activity toward MCF-7/HER2 cells. Extracellular MMP-9 activity 
within medium was measured by analyzing MMP-9 activity using gelatin zymography assay as described in the 
methods. A: Band intensity of MMP-9 activity after treatment with PGB-0-So for 24 h. B: Relative band intensity 
of MMP-9 activity. PGB-0-So showed the inhibiting of MMP-9 activity in single and combination with Doxorubicin 
10 nM after 24 h treatment. 
cells to confirm the interaction of sorbitol from 
compounds with specific proteins on the surface of 
MCF-7/HER2 cells.
 Furthermore, based on the cytotoxicity result, 
this study explored anti-metastatic activities of 
PGB-0-So. Anti-migratory effect of PGB-0-So 
was done using scratch wound healing assay. 
Based on this assay, PGB-0-So was combined 
with low concentration Dox (10 nM), because low 
concentration Dox can trigger cell migration by 
inducing epithelial-mesenchymal transition (EMT) 
(Bandyopadhyay, et al., 2010). The results revealed 
that inhibition of cell migration by PGB-0-So, either 
in single or combination treatment with Dox. The 
statistical test (p<0.05) on a 42 hour observation 
showed that PGB-0-So 4.5 µM and 18 µM 
concentrations in single or combination treatment 
with Dox significantly inhibited cell migration. The 
results of this study indicate that PGB-0-So was 
able to inhibit the activity of cell migration induced 
by Dox.
 The anti-migratory effect of  PGB-0-So is 
in line with research by Putri, et al. (2016) who 
reported anti-migration effect of the K-PGV-1, 
curcumin analogue, on 4T1 breast cancer cells. 
Curcumin was known to be able to inhibit the 
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progression of MCF-7 breast cancer cell metastasis 
through decreasing of urocinase-type plasminogen 
activator (uPA) protein expression that plays a role 
sin extracellular molecular signalling in the cell 
migration process (Zong, et al., 2012). The results 
of Lin, et al. (2009) also showed an inhibition of 
migration of lung-cell lung (A549) by curcumin 
through suppressing MMP-2 and -9 expression via 
the ER-sinyaling pathway.
 Matrix metalloproteinase (MMP) is known to 
play an important role in the invasion, metastasis 
and angiogenesis of cancer cells. One type of MMP 
playing important role in cell invasion is MMP-9 
(Bandyophadyay, 2014). Kim, et al. (2012) have 
reported that curcumin is able to suppress expression 
of MMP-9 induced by 12-O-tetradecanoylphorbol-
13-acetate TPA on MCF-7 breast cancer cells. 
Therefore, to confirm migration inhibition through 
decreasing MMP-9 expression by PGB-0-So, 
the gelatin zymograph assay was performed. In 
this test, at each treatment was added estradiol in 
order to increase the resulting MMP-9 expression 
(Nilsson, et al., 2007). 
 The results showed that treatment for 24 and 
48 hours with PGB-0-So 18 μM concentration 
in single or combination treatment with Dox 
decreased MMP-9 activity. This result is in line 
with previous study that PGB-0 decreased MMP-
9 expression in 4T1 breast cancer cells (unplished 
data). The possible mechanism of inhibition of 
MMP-9 activity in this finding is through inhibiton 
of NF-κB activation, MMP-9 transcription factor. 
The previous research stated that curcumin inhibit 
MMP-9 activity through down-regulation of NF-κB 
and reduction of AP-1 activation (Kim et al., 2012). 
As an analog curcumin, the molecular mechanism 
of PGB-0-So in inhibiting MMP-9 activity is also 
expected via the NF-κB pathway. 
CONCLUSION
 PGB-0-So is potential to be developed as 
anti-cancer agent to prevent metastasis in HER2-
overexpressed breast cancer cells. .
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